Opportunistic autoimmune disorders potentiated by immune-checkpoint inhibitors anti-CTLA-4 and anti-PD-1

Frontiers in Immunology

Volumn 5, Issue MAY, 2014, Pages

  Kong, Yi Chi M ^a   Flynn, Jeffrey C ^b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PROVIDENCE HOSPITAL   (United States)

Author keywords

Anti CTLA 4; Anti PD 1; Autoimmune disease; Immune checkpoint inhibitor; Tumor immunity

Indexed keywords

ALEMTUZUMAB; BMS 936559; CD45 ANTIGEN; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IPILIMUMAB; NIVOLUMAB; NY ESO 1 ANTIGEN; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; TICILIMUMAB; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

APOPTOSIS; AUTOIMMUNITY; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DOWN REGULATION; FOLLOW UP; GENOTYPE; HUMAN; IMMUNOMODULATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; NATURAL KILLER CELL; NONHUMAN; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; SHORT SURVEY; SIGNAL TRANSDUCTION; TUMOR IMMUNITY; TUMOR REGRESSION; UPREGULATION; VACCINATION;

EID: 84905503399     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00206     Document Type: Short Survey

References (80)

1. Kong YM, Wei W-Z, Tomer Y. Opportunistic autoimmune disorders: from immunotherapy to immune dysregulation. Ann N Y Acad Sci (2010) 1183:222-36. doi: 10.1111/j.1749-6632.2009.05138.x
2. Amos SM, Duong CP, Westwood JA, Ritchie DS, Junghans RP, Darcy PK, et al. Autoimmunity associated with immunotherapy of cancer. Blood (2011) 118:499-509. doi:10.1182/blood-2011-01-325266
3. Hamnvik OP, Larsen PR, Marqusee E. Thyroid dysfunction from antineoplastic agents. J Natl Cancer Inst (2011) 103:1572-87. doi:10.1093/jnci/djr373
4. Wolchok JD, Hodi FS, Weber JS, Allison JP, Urba WJ, Robert C, et al. Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci (2013) 1291:1-13. doi:10.1111/nyas.12180
5. 4 therapy in metastatic melanoma from the ipilimumab network. PLoS One (2013) 8:e53745. doi:10.1371/journal.pone.0053745
6. Ribas A, Kefford R, Marshall MA, Punt CJ, Haanen JB, Marmol M, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol (2013) 31:616-22. doi:10.1200/JCO.2012.44.6112
7. 4blockade. Clin Cancer Res (2007) 13:6681-8. doi:10.1158/1078-0432.ccr-07-0187
8. Beck KE, Blansfield JA, Tran KQ, Feldman AL, Hughes MS, Royal RE, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol (2006) 24:2283-9. doi:10.1200/jco.2005.04.5716
9. 4 have opposing effects on the response of T cells to stimulation. J Exp Med (1995) 182:459-65. doi:10.1084/jem.182.2.459
10. + regulatory T cell function. Science (2008) 322:271-5. doi:10.1126/science.1160062
11. 3+ regulatory T cells in the human immune system. Nat Rev Immunol (2010) 10:490-500. doi:10.1038/nri2785
12. 4. Science (1995) 270:985-8. doi:10.1126/science.270.5238.985
13. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity (1995) 3:541-7. doi:10.1016/1074-7613(95)90125-6
14. Kong YM, Morris GP, Brown NK, Yan Y, Flynn JC, David CS. Autoimmune thyroiditis: a model uniquely suited to probe regulatory T cell function. J Autoimmun (2009) 33:239-46. doi:10.1016/j.jaut.2009.09.004
15. + regulatory T cells are required for tolerance to experimental autoimmune thyroiditis induced by either exogenous or endogenous autoantigen. J Autoimmun (2009) 33:68-76. doi:10.1016/j.jaut.2009.03.010
16. Hoos A, Eggermont AM, Janetzki S, Hodi FS, Ibrahim R, Anderson A, et al. Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst (2010) 102:1388-97. doi:10.1093/jnci/djq310
17. Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol (2012) 30:2691-7. doi:10.1200/JCO.2012.41.6750
18. Jacobson DL, Gange SJ, Rose NR, Graham NMH. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol (1997) 84:223-43. doi:10.1006/clin.1997.4412
19. Torino F, Barnabei A, De VL, Salvatori R, Corsello SM. Hypophysitis induced by monoclonal antibodies to cytotoxic T lymphocyte antigen 4: challenges from a new cause of a rare disease. Oncologist (2012) 17:525-35. doi:10.1634/theoncologist.2011-0404
20. Corsello SM, Barnabei A, Marchetti P, De VL, Salvatori R, Torino F. Endocrine side effects induced by immune checkpoint inhibitors. J Clin Endocrinol Metab (2013) 98:1361-75. doi:10.1210/jc.2012-4075
21. Kong YM, Okayasu I, Giraldo AA, Beisel KW, Sundick RS, Rose NR, et al. Tolerance to thyroglobulin by activating suppressor mechanisms. Ann N Y Acad Sci (1982) 392:191-209. doi:10.1111/j.1749-6632.1982.tb36108.x
22. Kong YM, Giraldo AA, Waldmann H, Cobbold SP, Fuller BE. Resistance to experimental autoimmune thyroiditis: L3T4+ cells as mediators of both thyroglobulin-activated and TSH-induced suppression. Clin Immunol Immunopathol (1989) 51:38-54. doi:10.1016/0090-1229(89)90204-3
23. Kong YM, Jacob JB, Flynn JC, Elliott BE, Wei W-Z. Autoimmune thyroiditis as an indicator of autoimmune sequelae during cancer immunotherapy. Autoimmun Rev (2009) 9:28-33. doi:10.1016/j.autrev.2009.02.034
24. + regulatory T cell-depleted mice. Cancer Res (2005) 65:8471-8. doi:10.1158/0008-5472.CAN-05-0934
25. Jacob JB, Kong YM, Nalbantoglu I, Snower DP, Wei W-Z. Tumor regression following DNA vaccination and regulatory T cell depletion in neu transgenic mice leads to an increased risk for autoimmunity. J Immunol (2009) 182:5873-81. doi:10.4049/jimmunol.0804074
26. Kong YM, Lomo LC, Motte RW, Giraldo AA, Baisch J, Strauss G, et al. HLA-DRB1 polymorphism determines susceptibility to autoimmune thyroiditis in transgenic mice: definitive association with HLA-DRB1*0301 (DR3) gene. J Exp Med (1996) 184:1167-72. doi:10.1084/jem.184.3.1167
27. Jacob JB, Kong YM, Meroueh C, Snower DP, David CS, Ho Y-S, et al. Control of Her-2 tumor immunity and thyroid autoimmunity by MHC and regulatory T cells. Cancer Res (2007) 67:7020-7. doi:10.1158/0008-5472.CAN-06-4755
28. Lewis M, Giraldo AA, Kong YM. Resistance to experimental autoimmune thyroiditis induced by physiologic manipulation of thyroglobulin level. Clin Immunol Immunopathol (1987) 45:92-104. doi:10.1016/0090-1229(87)90115-2
29. Kari S, Flynn JC, Zulfiqar M, Snower DP, Elliott BE, Kong YM. Enhanced autoimmunity associated with induction of tumor immunity in thyroiditis-susceptible mice. Thyroid (2013) 23:1590-9. doi:10.1089/thy.2013.0064
30. Caturegli P, Lupi I, Landek-Salgado M, Kimura H, Rose NR. Pituitary autoimmunity: 30 years later. Autoimmun Rev (2008) 7:631-7. doi:10.1016/j.autrev.2008.04.016
31. 4 antibody in patients with metastatic melanoma. J Immunother (2006) 29:455-63. doi:10.1097/01.cji.0000208259.73167.58
32. Eggermont AM, Spatz A, Robert C. Cutaneous melanoma. Lancet (2014) 383:816-27. doi:10.1016/S0140-6736(13)60802-8
33. Landek-Salgado MA, Leporati P, Lupi I, Geis A, Caturegli P. Growth hormone and proopiomelanocortin are targeted by autoantibodies in a patient with biopsy-proven IgG4-related hypophysitis. Pituitary (2012) 15:412-9. doi:10.1007/s11102-011-0338-8
34. Smith CJ, Bensing S, Burns C, Robinson PJ, Kasperlik-Zaluska AA, Scott RJ, et al. Identification of TPIT and other novel autoantigens in lymphocytic hypophysitis: immunoscreening of a pituitary cDNA library and development of immunoprecipitation assays. Eur J Endocrinol (2012) 166:391-8. doi:10.1530/EJE-11-1015
35. Lupi I, Raffaelli V, Di Cianni G, Caturegli P, Manetti L, Ciccarone AM, et al. Pituitary autoimmunity in patients with diabetes mellitus and other endocrine disorders. J Endocrinol Invest (2013) 36:127-31. doi:10.1007/BF03346747
36. Huang RR, Jalil J, Economou JS, Chmielowski B, Koya RC, Mok S, et al. CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans. Clin Cancer Res (2011) 17:4101-9. doi:10.1158/1078-0432.CCR-11-0407
37. Weber JS, Hamid O, Chasalow SD, Wu DY, Parker SM, Galbraith S, et al. Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma. J Immunother (2012) 35:89-97. doi:10.1097/CJI.0b013e31823aa41c
38. 4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci U S A (2008) 105:20410-5. doi:10.1073/pnas.0810114105
39. + T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci U S A (2011) 108:16723-8. doi:10.1073/pnas.1110814108
40. 1 antibody in patients with metastatic melanoma. J Immunother (2009) 32:884-5. doi:10.1097/CJI.0b013e3181affbf0
41. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 363:711-23. doi:10.1056/NEJMoa1003466
42. Venuprasad K, Kong YM, Farrar MA. Control of Th2-mediated inflammation by regulatory T cells. Am J Pathol (2010) 177:525-31. doi:10.2353/ajpath.2010.090936
43. 4 therapy against melanoma. J Exp Med (2013) 210:1695-710. doi:10.1084/jem.20130579
44. Zitvogel L, Tanchot C, Granier C, Tartour E. Following up tumor-specific regulatory T cells in cancer patients. Oncoimmunology (2013) 2:e25444. doi:10.4161/onci.25444
45. Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C, et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med (2012) 18:1254-61. doi:10.1038/nm.2883
46. Bonertz A, Weitz J, Pietsch DH, Rahbari NN, Schlude C, Ge Y, et al. Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. J Clin Invest (2009) 119:3311-21. doi:10.1172/JCI39608
47. 4 T cells identified in human metastatic melanoma: peptide vaccination results in selective expansion of Th1-like counterparts. Cancer Res (2009) 69:8085-93. doi:10.1158/0008-5472.CAN-09-2226
48. Schmidt HH, Ge Y, Hartmann FJ, Conrad H, Klug F, Nittel S, et al. HLA Class II tetramers reveal tissue-specific regulatory T cells that suppress T-cell responses in breast carcinoma patients. Oncoimmunology (2013) 2:e24962. doi:10.4161/onci.24962
49. Wherry EJ. T cell exhaustion. Nat Immunol (2011) 12:492-9. doi:10.1038/ni.2035
50. 4 and PD-1 blockade as cancer immunotherapy. J Leukoc Biol (2013) 94:25-39. doi:10.1189/jlb.1212621
51. Callahan MK, Wolchok JD. At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. J Leukoc Biol (2013) 94:41-53. doi:10.1189/jlb.1212631
52. Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE, et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood (2009) 114:1537-44. doi:10.1182/blood-2008-12-195792
53. 25Hi regulatory T cells. Int Immunol (2009) 21:1065-77. doi:10.1093/intimm/dxp072
54. Velcheti V, Schalper KA, Carvajal DE, Anagnostou VK, Syrigos KN, Sznol M, et al. Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest (2014) 94:107-16. doi:10.1038/labinvest.2013.130
55. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 366:2443-54. doi:10.1056/NEJMoa1200690
56. Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity (1999) 11:141-51. doi:10.1016/S1074-7613(00)80089-8
57. Okazaki T, Tanaka Y, Nishio R, Mitsuiye T, Mizoguchi A, Wang J, et al. Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med (2003) 9:1477-83. doi:10.1038/nm955
58. PD-1 inhibitor becomes "breakthrough therapy". Cancer Discov (2013) 3:OF14. doi:10.1158/2159-8290.CD-NB2013-074
59. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med (2013) 369:134-44. doi:10.1056/NEJMoa1305133
60. Kyi C, Postow MA. Checkpoint blocking antibodies in cancer immunotherapy. FEBS Lett (2014) 588:368-76. doi:10.1016/j.febslet.2013.10.015
61. Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol (2014) 32:1020-30. doi:10.1200/JCO.2013.53.0105
62. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 366:2455-65. doi:10.1056/NEJMoa1200694
63. Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol (2001) 2:261-8. doi:10.1038/85330
64. Tseng SY, Otsuji M, Gorski K, Huang X, Slansky JE, Pai SI, et al. B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J Exp Med (2001) 193:839-46. doi:10.1084/jem.193.7.839
65. Fife BT, Pauken KE, Eagar TN, Obu T, Wu J, Tang Q, et al. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat Immunol (2009) 10:1185-92. doi:10.1038/ni.1790
66. 16 melanoma tumors. Proc Natl Acad Sci U S A (2010) 107:4275-80. doi:10.1073/pnas.0915174107
67. 4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res (2013) 73:3591-603. doi:10.1158/0008-5472.CAN-12-4100
68. 4. J Exp Med (2013) 210:1389-402. doi:10.1084/jem.20130066
69. 4 blockade. Science (1996) 271:1734-6. doi:10.1126/science.271.5256.1734
70. + regulatory cells that control intestinal inflammation. J Exp Med (2000) 192:295-302. doi:10.1084/jem.192.2.295
71. Hurwitz AA, Foster BA, Kwon ED, Truong T, Choi EM, Greenberg NM, et al. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res (2000) 60:2444-8.
72. Ansari MJI, Salama AD, Chitnis T, Smith RN, Yagita H, Akiba H, et al. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med (2003) 198:63-9. doi:10.1084/jem.20022125
73. Kwidzinski E, Bunse J, Aktas O, Richter D, Mutlu L, Zipp F, et al. Indolamine 2,3-dioxygenase is expressed in the CNS and down-regulates autoimmune inflammation. FASEB J (2005) 19:1347-9. doi:10.1096/fj.04-3228fje
74. 4 monotherapy improves antitumor effects. J Clin Invest (2012) 122:3718-30. doi:10.1172/JCI61931
75. + regulatory T cells cure murine colitis: the role of IL-10, TGF-β, and CTLA4. J Immunol (2003) 171:5012-7. doi:10.4049/jimmunol.171.10.5012
76. 4 in patients with autoimmune thyroid disease. J Immunol (2000) 164:5015-8. doi:10.4049/jimmunol.164.10.5015
77. 4 inhibits TcR-specific activation signals and prevents collagen-induced arthritis. Proc Natl Acad Sci U S A (2008) 105:19875-80. doi:10.1073/pnas.0805198105
78. 4/B7 interactions results in exacerbated clinical and histologic disease in an actively-induced model of experimental allergic encephalomyelitis. J Neuroimmunol (1997) 73:57-62.
79. 4 and PD-1 pathways. Immunol Rev (2008) 224:166-82. doi:10.1111/j.1600-065X.2008.00662.x
80. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med (2013) 369:122-33. doi:10.1056/NEJMoa1302369